• Policy
• Essential medical devices will be designated by next year
• by Lee, Hye-Kyung Mar 20, 2024 05:44am

• Policy
• Liver cancer therapy, ‘Stivarga’ set for 2nd RSA renewal
• by Lee, Tak-Sun Mar 19, 2024 05:44am

• Policy
• Sotyktu, Adtralza set for reimbursement listing
• by Lee, Tak-Sun Mar 18, 2024 05:49am

• Policy
• Anticipated shortage of Merck’s fertility drug ‘Gonal-F’
• by Lee, Hye-Kyung Mar 15, 2024 05:49am

• Policy
• Gov't will specify scope of expense report details disclosed
• by Lee, Jeong-Hwan Mar 15, 2024 05:49am

• Policy
• HIRA’s CDDC seeks to revise current regulations
• by Lee, Tak-Sun Mar 15, 2024 05:48am

• Policy
• MFDS starts regulatory innovation program for Big Techs
• by Lee, Hye-Kyung Mar 14, 2024 05:42am

• Policy
• Chong Kun Dang also enters low-intensity atorvastatin mkt
• by Lee, Hye-Kyung Mar 14, 2024 05:42am

• Policy
• Poteligeo and Livtencity may likely be reimbursed in April
• by Lee, Tak-Sun Mar 14, 2024 05:42am

• Policy
• “Calling for promotion of substitute drug dispensation“
• by Lee, Jeong-Hwan Mar 13, 2024 05:32am